The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
CREDIT DESIGNATION STATEMENT
The AACR has designated this live activity for a maximum of 21.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CLAIMING (CME) CREDIT
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this continuing medical education activity must complete the CME Request for Credit Survey below. Certificates will only be issued to those who complete the survey. CME certificates will be sent by email after the completion of the activity.
STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE AND LEARNING OBJECTIVES
In the era of the cancer genome projects, such as The Cancer Genome Atlas (TCGA), vast and complex epi/genomic and proteomic information annotated with clinical parameters will be generated. It is envisioned that translation of these data will require multidisciplinary integrated systems biology approaches not typical of traditional basic and translational research. With this vast and complex data, there is a great need to convert these data into meaningful functional/mechanistic insights that can advance our understanding of cancer pathogenesis and enable development of new diagnostic and therapeutic agents.
In order for the true potential of these large-scale cancer genomics efforts to be fully realized, it is imperative that biologists, translational scientists, physicians and clinicians with disease expertise learn to use these data. Conversely, computational biologists with expertise to analyze these complex data must learn to ask disease-relevant questions with these data to enable and facilitate translation. This conference will bring these physicians and scientists together.
In addition, there are several questions that still need to be addressed in order to effectively interpret these data: Are significant statistical correlations sufficient to harness the full clinical potential of these complex data sets in a manner that will change the practice of cancer medicine? Who will be the “users” of these data? After participating in this CME activity, participants will be able to:
- Identify and distinguish key pathogenetic events from noise in respect to genomic data;
- Assess the diagnostic, prognostic or predictive significance of genomic changes;
- Design effective experiments to retrospectively and prospectively validate genomic-based molecular biomarkers and therapeutic targets;
- Facilitate interactions among individuals from different research disciplines that must work/interact more closely to efficiently translate cancer genome data;
- Evaluate the needs beyond statistical significance to go from genomics to therapeutics/diagnostics;
- Utilize the knowledge, expertise and experiences of groups that have been developing/optimizing standard molecular or cell biology assays to the high-throughput level; and to increase efforts to develop and improve such systems for functionalizing the genome data; and
- Enhance uses of The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) data.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Scientific Program Committee member and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
QUESTIONS ABOUT CME?
Please contact the Office of CME at (215) 440-9300 or firstname.lastname@example.org.